Effect of SGLT2 Inhibitors on Anemic CKD Patients

Sohag University

Status: Not yet enrolling

Conditions: Anemia in CKD Patients

Treatments: Drug: SGLT2 inhibitor

Study type: Observational

Funder types: Other

Identifiers

NCT07334145

soh_med__25_12_6MS

Details and patient eligibility

About

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age more than 18 years
• CKD stage 1_4
• baseline hemoglobin 8.5 to 12.9 g/dl
• stable anemia regimen for more than 8 weeks

Exclusion criteria

• dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Trial design

60 participants in 1 patient group

CKD patients stage 1_4

Treatment:

Drug: SGLT2 inhibitor